SPYR, Inc. has finalized its change of control with Ledjr AI, appointing Mohammed Siddiqi as CEO and director. The company plans to conduct a PCAOB-audited financial review and file an SEC registration statement within 90 days, aiming for SEC reporting status and a national exchange listing. SPYR is also preparing to change its name and trading symbol to reflect Ledjr's business. This marks a strategic shift after SPYR's court-supervised restoration and significant debt reduction.
SPYR's change of control is the subject, with this Pluang market snapshot as of Oct 24, 2026 02:11 WIB: Among 150 Technology-sector US stocks, 90 rose and 59 fell. Notable movers include ACN at USD 247.74 with a 4.25% decline and 99% sell order activity, ENTG at USD 133.68 with a 4.19% rise and 100% buy order activity, and ESTC at USD 102.25 with a 4.11% rise and 100% sell order activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
